Biotech Values

[ghmm]

Potent, dose-dependent, antiviral activity after 4 weeks treatment with triple therapy with 4.3, 5.5 and 5.3 log 10 IU/mL reduction for 75, 150 and 200 mg QD groups, respectively, compared to 1.5 in the placebo group

I find the 4.3 (vs. 5.5 in the treatment naive and similar at higher doses) an interesting observation. InterMune's monotherapy arm also had noticably lower viral load reduction and in the INFORM extension they are using much higher doses. I guess it is not surprising that non-responders may do better with higher doses.

I believe telaprevir is using the same daily dosing for the BID regimen as their TID whereas InterMune's 2B is using much higher daily dosing in the BID then the TID. I am not sure if telaprevir is limited in total daily dosing or if they are concerned about the side effects or perhaps they have discovered in longer duration studies its less of an issue. It will be interesting to see what the BID final SVR results are relative to the TID.